32
Participants
Start Date
March 4, 2021
Primary Completion Date
December 31, 2024
Study Completion Date
December 31, 2024
Keytruda Injectable Product
PD-1 inhibitor antibody
Yervoy Injectable Product
Anti-CTLA-4 antibody
GM-CSF
1 mL injected into each non-ablative cryosurgical freezing zone. Daily injection administered subcutaneously. 250 mcg daily injections for a total of 25 days after each treatment.
Non-ablative Cryosurgical freezing
To induce immediate necrosis and necroptosis and a rim of injured cancer cells, thereby exposing a complete range of patient-specific tumor antigens that are specific to the treated subject.
Florida Endovascular and Interventional, Miami Lakes
Vincere Cancer Center, Scottsdale
Lead Sponsor
ImmunSYS, LLC
OTHER